Physician profile
Mark Jackson
NPI 1205815982
$821.91
in general payments reported to CMS, 2019-2025
23 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.00 · 2022: $171 · 2023: $260 · 2024: $157 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $144.93 | 2022-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Convatec INC. | $79.26 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $76.02 | 2022-2025 | Euflexxa |
| Pacira Pharmaceuticals Incorporated | $54.01 | 2022-2024 | Exparel, Zilretta, Iovera |
| Avanos Medical | $53.81 | 2025 | Generator |
| Abbvie INC. | $47.42 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $44.96 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $43.58 | 2024-2025 | |
| Amgen INC. | $32.79 | 2023 | Evenity, Prolia |
| Polynovo North America LLC | $28.29 | 2024 | Novosorb Btm |
| Acacia Pharma INC | $27.76 | 2022 | |
| Csl Behring | $19.42 | 2022 | |
| Averitas Pharma INC. | $18.99 | 2023 | Qutenza |
| Baxter Healthcare | $18.36 | 2025 | Perclot |
| Kowa Pharmaceuticals America, INC. | $17.48 | 2023 | Seglentis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $17.23 | 2023 | Andexxa |
| Pfizer INC. | $15.08 | 2025 | |
| Kci USA, INC. | $14.79 | 2022 | |
| Heron Therapeutics, INC. | $14.78 | 2024 | Zynrelef |
| Bioventus LLC | $14.35 | 2021 | |
| Solventum Corporation | $13.61 | 2025 | Prevena, V.A.C. Veraflo |
| Grt US Holding, INC. | $12.51 | 2021 | |
| Paratek Pharmaceuticals, INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.